Adherence to growth hormone (GH) therapy in na&#239;ve to treatment GH-deficient children : data of the Italian Cohort from the Easypod Connect Observational Study (ECOS) by C. Centonze et al.
Vol.:(0123456789) 
Journal of Endocrinological Investigation (2019) 42:1241–1244 
https://doi.org/10.1007/s40618-019-01046-1
ORIGINAL ARTICLE
Adherence to growth hormone (GH) therapy in naïve to treatment 
GH‑deficient children: data of the Italian Cohort from the Easypod 
Connect Observational Study (ECOS)
C. Centonze1 · C. Guzzetti2 · G. Orlando1 · S. Loche2 on behalf of the Italian ECOS Investigators
Received: 29 January 2019 / Accepted: 1 April 2019 / Published online: 9 April 2019 
© The Author(s) 2019
Abstract
Background With the use of non-objective measurement, adherence to growth hormone (GH) therapy has been reported 
suboptimal in a large proportion of patients, and poor adherence has been shown to affect short-term growth response in 
patients receiving GH treatment.
Objective The Easypod™ electronic device allows objective measurement of adherence. In this study, we report 3-year 
prospective adherence data of the Italian cohort of naïve GH deficient (GHD) children extrapolated from the Easypod Con-
nect Observational Study (ECOS) database.
Patients and methods Seventy-three GHD children naïve to GH treatment were included in the analysis. 22 Italian centers 
participated in the study.
Results Mean adherence rate was consistently above 85% across the 3-year observation period. Particularly, mean adher-
ence was 88.5%, 86.6%, and 85.7% after 1, 2 and 3 years, respectively. Mean (± SD) height-SDS increase after the first year 
was 0.41 (± 0.38).
Conclusions The majority of naïve GHD children starting GH treatment with Easypod maintained an adherence rate > 85% 
up to 3 years. Easypod is a useful tool to follow-up patients’ adherence allowing timely intervention to improve optimal 
treatment for these patients.
Keywords ECOS · Short stature · Children · Growth hormone · GHD
Introduction
Human recombinant growth hormone (h-rGH) is currently 
used to treat a variety of clinical conditions associated with 
short stature, including GH deficiency (GHD), Turner syn-
drome, Prader–Willi syndrome, children born small for ges-
tational age (SGA), and children with chronic renal failure 
[1]. The growth response to GH therapy is influenced by a 
number of factors which include, among others, the initial 
diagnosis, the age of the patient, the dose of GH adminis-
tered as well as individual responsiveness [2–4]. Although 
adherence to medication is a well-known clinical problem 
affecting several chronic diseases, measuring adherence is 
generally difficult and mostly based on patient self-reported 
questionnaires, prescription records, or vials counting [5]. 
With the use of non-objective measurement, adherence to 
GH therapy has been reported suboptimal in up to 77% of 
patients in different studies [6–12]. Poor adherence has been 
shown to be related to several factors including lower socio-
economic or educational status, injections considered diffi-
cult, lack of choice of injection device, use of conventional 
syringe rather than automatic pen injection device, and 
discomfort with injections [13]. Furthermore, poor adher-
ence has been shown to affect short-term growth response 
in patients receiving GH treatment [11, 12, 14].
The easypod™ electronic device allows objective meas-
urement of adherence, and short-term studies have recently 
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shown a good acceptance and adherence in patients taking 
h-rGH via this device [15–18]. Easypod allows transmission 
of injections’ data (real time recorded dose and timing) by 
a wireless transmitter to physician, thus allows to examine 
individual patients’ adherence remotely in real time settings. 
Easypod Connect Platform (ECP), as a whole, provides an 
e-health solution to improve patient management by remote 
examination and control of adherence to h-r.
The Easypod Connect Observational Study (ECOS) is a 
prospective international 5-year investigation designed to 
assess adherence to GH treatment in patients taking h-rGH 
via the Easypod device for several conditions. Data from this 
large international study including 1203 patients from 24 
different countries have been recently published, and shown 
that median adherence rate in the entire cohort was main-
tained over 80% in the first 3 years, and declined thereafter 
[19]. This study has also reported adherence rate across the 
5-year observation period in the subgroup of naïve GHD 
patients of different ethnic origin, and shown that mean 
adherence rate in the first 2 years was > 80%, and > 75% in 
the third year irrespective of the cause of GHD. In this study, 
we report 3-year prospective adherence data of the Italian 
cohort of naïve GHD children extrapolated from the ECOS 
database.
Patients and methods
Seventy-three GHD children naïve to GH treatment were 
recruited in 22 Italian centers and included in the analy-
sis. Their main clinical characteristics are summarized in 
Table 1. The diagnosis of GHD was performed in each par-
ticipating center according to standard endocrine practice. 
Seventy children had idiopathic GHD, two had organic GHD 
and one had congenital GHD. The study was approved by 
the local ethical committees, and written informed con-
sent was obtained from the patients and/or from their legal 
guardians prior to their enrollment in the study. As reported 
in the large ECOS study [19], patients were enrolled in the 
database and after an initial baseline visit, they were seen 
1–4 times/year. Adherence rate was derived from the Easy-
pod device and calculated as the percentage of injections 
recorded versus prescribed.
Results
Adherence data were available for 65 patients after 1 year, 
for 40 patients after 2 years, and for 18 patients after 3 years 
(Fig. 1). Mean adherence rate was consistently above 85% 
across the 3-year observation period (Fig. 2). Particularly, 
mean adherence was 88.5%, 86.6%, and 85.7% after 1, 2 and 
3 years, respectively. Mean adherence rate for individual 
treatment period (from the beginning of treatment to the 
last complete week of available data for each patient) was 
86.51% (Fig. 2). Mean (± SD) height-SDS increase after the 
first year was 0.41 (± 0.38) (Table 1). We found no signifi-
cant correlation between the level of adherence and growth 
outcome after the first year of treatment.
Discussion
We have shown in this study that in the ECOS Italian cohort 
of GHD patients naïve to GH therapy the mean level of 
adherence is maintained > 85% for up to 3 years. The analy-
sis of this subset of patients from a single country confirms 
the observation of the global ECOS data [19]. The recent 
large ECOS study has shown, in fact, that in naïve GHD 
patients, the adherence rate is maintained > 80% in the first 
2 years, and declines thereafter. Of note, in the subset of 
patients of the italian cohort of this study, mean adherence 
rate was slightly better, and did not decline in the third year 
as in the large ECOS study, confirming our previous obser-
vation that children with GHD treated with r-hGH via the 
Table 1  Main clinical 
characteristics of the children 
studied
Age, years
 Mean (SD) 9.78 (3.20)
 Median 10.00
 Q1; Q3 8.00; 12.00
 Min; max 1.0; 15.0
Sex, n (%)
 Female 35 (47.9)
 Male 38 (52.1)
Change in height SDS (n = 70)
 Mean (SD) 0.42 (0.38)
 Median 0.41
 Q1; Q3 0.18; 0.61
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Fig. 1  Number of patients with prospective adherence data over the 
study period
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Easypod device generally have a good adherence to treat-
ment [17]. In our previous short-term study, we recorded 
high levels of adherence in 97 patients taking r-hGH, with 
57% of them having an adherence rate > 92%. Other short-
term studies have confirmed good adherence in pediatric 
patients receiving h-rGH via the Easypod device, ranging 
from 87.5 to 99% [16–18, 20].
In the present study, treatment was associated with the 
expected increase in height. The observed variability of the 
first year response is in line with previous findings obtained 
from analyses of large databases [21, 22]. The variability of 
the growth response is a well known phenomenon, possibly 
related to the heterogeneity of patients in term of severity of 
GHD as well as individual responsiveness [3].
The diagnosis of growth hormone deficiency (GHD) is 
currently based on clinical and auxological assessment, 
with the supporting evidence from biochemical and MRI 
studies [23]. The diagnostic workup in a patient with sus-
pected GHD includes evaluation of GH secretion by means 
of stimulation testing. The Italian Medicine Agency (AIFA) 
regulates the modalities of growth hormone prescription to 
GHD children, as well as the criteria for diagnosis [24]. 
Complying with the prescription criteria is mandatory for 
endocrinologists who can only prescribe GH within hos-
pitals specifically accredited by government. Therefore, all 
GHD patients included in the ECOS in Italy fulfill the same 
national standards for diagnostic criteria. Furthermore, all 
patients of our study are of Caucasian origin. Based on these 
premises, our sample population can be considered homoge-
neous since our patients share the same endocrine phenotype 
as well as ethnic origin. In this regard, it should be pointed 
out that poor adherence has been correlated with ethnic ori-
gin [12] as well as with training by non-hospital staff or no 
training rather than training by hospital staff [6].
In short-term studies poor adherence has been shown to 
be related with the growth outcome [11, 12, 14]. The global 
ECOS study [19] has reported a positive correlation between 
adherence rate and growth response in the GHD patients. We 
found no correlation between the level of adherence and the 
growth outcome after the first year, possibly due to the small 
number of subjects and to the fact that adherence values 
were skewed toward high positive levels. Our results are in 
agreement with those recently reported by Van Dommelen 
et al. [25] who showed that average adherence in the first 
year was not associated with first year growth response in 
children with GHD but was highly correlated with growth 
response in the second year and 0–2 years in total.
In conclusion, we have shown that the majority of naïve 
GHD children starting GH treatment with Easypod in Italy 
maintained an adherence rate > 85% up to 3 years. Easypod 
is a useful tool to follow-up patients’ adherence allowing 
timely intervention to improve optimal treatment for these 
patients.
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